WINTON GROUP Ltd Purchases 1,006 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

WINTON GROUP Ltd lifted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 43.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,343 shares of the company's stock after purchasing an additional 1,006 shares during the quarter. WINTON GROUP Ltd's holdings in Medpace were worth $1,111,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. R Squared Ltd bought a new stake in Medpace during the fourth quarter worth approximately $30,000. SBI Securities Co. Ltd. acquired a new position in shares of Medpace during the 4th quarter valued at $31,000. Jones Financial Companies Lllp raised its stake in shares of Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after buying an additional 110 shares in the last quarter. Lindbrook Capital LLC lifted its holdings in shares of Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after buying an additional 29 shares during the period. Finally, True Wealth Design LLC lifted its holdings in shares of Medpace by 16,800.0% in the third quarter. True Wealth Design LLC now owns 169 shares of the company's stock valued at $56,000 after buying an additional 168 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of Medpace stock traded up $10.50 during trading on Wednesday, hitting $308.23. 240,441 shares of the stock traded hands, compared to its average volume of 301,409. The stock has a market cap of $9.39 billion, a P/E ratio of 24.39, a PEG ratio of 3.81 and a beta of 1.47. The company has a fifty day moving average price of $334.26 and a two-hundred day moving average price of $338.52. Medpace Holdings, Inc. has a twelve month low of $289.01 and a twelve month high of $459.77.

Remove Ads

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts' consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Ratings Changes

MEDP has been the subject of a number of research analyst reports. Leerink Partnrs raised shares of Medpace to a "hold" rating in a report on Monday, March 24th. Robert W. Baird increased their target price on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. Finally, Leerink Partners assumed coverage on shares of Medpace in a research report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target on the stock. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $376.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.